AMG 609 / Amgen - LARVOL DELTA

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=47 | Completed | Sponsor: Amgen | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Non-alcoholic Fatty Liver Disease

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=47 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | Trial completion date: May 2024 ➔ Jul 2023 | Trial primary completion date: May 2024 ➔ Jul 2023

Enrollment closed • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Amgen | N=106 ➔ 56 | Trial completion date: Nov 2023 ➔ May 2024 | Trial primary completion date: Nov 2023 ➔ May 2024

Enrollment change • Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - P1 | N=106 | Recruiting | Sponsor: Amgen | Trial completion date: May 2023 ➔ Nov 2023 | Trial primary completion date: May 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Hepatology • Non-alcoholic Fatty Liver Disease